Aptevo Therapeutics annual capital expenditures (capex)
2015
2016
2017
2018
2019
2020
2021
2022
Aptevo Therapeutics Capital Expenditures (CapEx) Growth & History (APVO)
Aptevo Therapeutics's capital expenditures (capex) was $29,000 for fiscal 2022.
View full Aptevo Therapeutics company overviewAptevo Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | $29,000 | −$684,000 | −95.93% |
| 2021 | 2021-12-31 | $713,000 | $625,000 | +710.23% |
| 2020 | 2020-12-31 | $88,000 | −$65,000 | −42.48% |
| 2019 | 2019-12-31 | $153,000 | −$823,000 | −84.32% |
| 2018 | 2018-12-31 | $976,000 | −$426,000 | −30.39% |
| 2017 | 2017-12-31 | $1.4M | −$1.1M | −44.19% |
| 2016 | 2016-12-31 | $2.5M | $985,000 | +64.51% |
| 2015 | 2015-12-31 | $1.5M | — | — |
Aptevo Therapeutics quarterly capital expenditures (capex)
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q3.22
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2022 | 2022-09-30 | $4,000 | −$9,000 | −69.23% |
| Q4 2021 | 2021-12-31 | $118,000 | — | — |
| Q3 2021 | 2021-09-30 | $13,000 | — | — |
| Q2 2021 | 2021-06-30 | $391,000 | — | — |
| Q1 2021 | 2021-03-31 | $191,000 | — | — |
| Q4 2019 | 2019-12-31 | $0 | −$49,000 | — |
| Q3 2019 | 2019-09-30 | $0 | −$360,000 | — |
| Q2 2019 | 2019-06-30 | $0 | −$94,000 | — |
| Q1 2019 | 2019-03-31 | $153,000 | −$320,000 | −67.65% |
| Q4 2018 | 2018-12-31 | $49,000 | −$248,000 | −83.50% |
| Q3 2018 | 2018-09-30 | $360,000 | $225,000 | +166.67% |
| Q2 2018 | 2018-06-30 | $94,000 | −$82,000 | −46.59% |
| Q1 2018 | 2018-03-31 | $473,000 | −$321,000 | −40.43% |
| Q4 2017 | 2017-12-31 | $297,000 | −$282,000 | −48.70% |
| Q3 2017 | 2017-09-30 | $135,000 | $89,000 | +193.48% |
| Q2 2017 | 2017-06-30 | $176,000 | −$732,000 | −80.62% |
| Q1 2017 | 2017-03-31 | $794,000 | −$277,000 | −25.86% |
| Q4 2016 | 2016-12-31 | $579,000 | — | — |
| Q3 2016 | 2016-09-30 | $46,000 | −$392,000 | −89.50% |
| Q2 2016 | 2016-06-30 | $908,000 | — | — |
| Q1 2016 | 2016-03-31 | $1.1M | — | — |
| Q3 2015 | 2015-09-30 | $438,000 | — | — |
Aptevo Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Aptevo Therapeutics's capital expenditures (capex) decreased from $1.4M to $29,000, a change of −$1.4M. The latest reported quarter, Q3 2022, shows $4,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aptevo Therapeutics source filings ↗